CardioVascular and Interventional Radiology

, Volume 42, Issue 1, pp 41–47 | Cite as

Reiterative Radiofrequency Ablation in the Management of Pediatric Patients with Hepatoblastoma Metastases to the Lung, Liver, or Bone

  • Steven Yevich
  • Marco Calandri
  • Guillaume Gravel
  • Brice Fresneau
  • Laurence Brugières
  • Dominique Valteau-Couanet
  • Sophie Branchereau
  • Christophe Chardot
  • Isabelle Aerts
  • Thierry de Baere
  • Lambros Tselikas
  • Frederic Deschamps
Clinical Investigation Interventional Oncology
Part of the following topical collections:
  1. Interventional Oncology


Background and Purpose

Conventional treatments of systemic chemotherapy and surgical resection for recurrent or metastatic hepatoblastoma (HB) may be inhibitive for the pediatric patient and family who have already been through extensive therapies. This single-institution case series evaluates the safety and efficacy of percutaneous radiofrequency ablation (RFA) in the management of metastatic HB.

Materials and Methods

Between March 2008 and February 2015, RFA was used as part of multidisciplinary management for HB recurrence or metastasis in 5 children (median 5.0 years old) in an attempt to provide locoregional control and preclude additional surgery. Combined local treatments of 38 metachronous metastases included surgical metastasectomy (14 lesions: 7 lung, 7 liver), percutaneous RFA (23 lesions: 21 lung, 1 liver, 1 bone), and stereotactic radiotherapy (1 liver lesion).


For lesions treated with RFA (median diameter 6 mm, range 3–15 mm), local control was achieved in 22/23 metastases (95.6%) with median follow-up of 30.1 months after RFA (range 18.9–65.7). Median hospitalization was 3 days (2–7), with major complications limited to 1 pneumothorax requiring temporary small-caliber chest tube. Four children remain in complete remission with median follow-up of 67 months (range 41.2–88.8) after primary tumor resection, with mean disease-free survival of 31.7 months after last local treatment. One child succumbed to rapidly progressive disease 12 months after RFA (23.9 months after primary tumor resection).


RFA provides a safe and effective reiterative treatment option in the multidisciplinary management of children with metastatic HB.


Hepatoblastoma Pediatric Radiofrequency Ablation Metastasis 





Radiofrequency ablation


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Darbari A, Sabin KM, Sahpiro CN, et al. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38(3):560–6.CrossRefGoogle Scholar
  2. 2.
    Mann JR, Kasthuri N, Raafat F, et al. Malignant hepatic tumours in children: incidence, clinical features, and aetiology. Pediatr Perinat Epidemiol. 1990;4(3):276–89.CrossRefGoogle Scholar
  3. 3.
    Browne M, Sher D, Grant D, et al. Survival after liver transplantation for hepatoblastoma: a 2-center experience. J Pediatr Surg. 2008;43(11):1973–81.CrossRefGoogle Scholar
  4. 4.
    Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584–90.CrossRefGoogle Scholar
  5. 5.
    Tannuri AC, Cristofani LM, Teixeira RA, et al. New concepts and outcomes for children with hepatoblastoma based on the experience of a tertiary center over the last 21 years. Clinics (Sao Paolo). 2015;70:387–92.CrossRefGoogle Scholar
  6. 6.
    Fuchs J, Rydzynski J, Schweinitz DV, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002;95(1):172–82.CrossRefGoogle Scholar
  7. 7.
    Ismail H, Broniszczak D, Kalicinski P, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg. 2012;47(7):1331–9.CrossRefGoogle Scholar
  8. 8.
    Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update. Curr Opin Pediatr. 2014;26(3):362–9.CrossRefGoogle Scholar
  9. 9.
    Semeraro M, Branchereau S, Maibach R, et al. Relapses in hepatoblastoma patients: clinical characteristics and outcome-experience of the international childhood liver tumor strategy group (SIOPEL). Eur J Cancer. 2013;49(4):915–22.CrossRefGoogle Scholar
  10. 10.
    Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a paediatric oncology group phase II study. J Clin Oncol. 2002;20:3438–44.CrossRefGoogle Scholar
  11. 11.
    Matsunaga T, Sasaki F, Ohira M, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int. 2003;19:142–6.PubMedGoogle Scholar
  12. 12.
    Horton JD, Lee S, Brown SR, et al. Survival trends in children with hepatoblastoma. Pediatr Surg Int. 2009;25(5):407–12.CrossRefGoogle Scholar
  13. 13.
    Meyers RL, Katzenstein HM, Krailo M, et al. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg. 2007;42(12):2050–6.CrossRefGoogle Scholar
  14. 14.
    Pham TH, Iqbal CW, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg. 2007;42(5):834–9.CrossRefGoogle Scholar
  15. 15.
    Yada K, Ishibashi H, Mori H, et al. The role of surgical treatment in the multidisciplinary therapy for hepatoblastoma. Hepatogastroenterology. 2014;61(131):553–6.PubMedGoogle Scholar
  16. 16.
    Trobaugh-Lotrario AD, Feusner JH. Relapsed hepatoblastoma. Pediatr Blood Cancer. 2012;59:813–7.CrossRefGoogle Scholar
  17. 17.
    Shi Y, Geller JI, Ma IT, et al. Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy. J Pediatr Surg. 2016;51(4):525–9.CrossRefGoogle Scholar
  18. 18.
    Carcellar A, Blanchard H, Champagne J, et al. Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma. J Pediatr Surg. 2001;36:755–9.CrossRefGoogle Scholar
  19. 19.
    Wanaguru D, Shun A, Price N, Karpelowsky J. Outcomes of pulmonary metastases in hepatoblastoma–is the prognosis always poor? J Pediatr Surg. 2013;48(12):2474–8.CrossRefGoogle Scholar
  20. 20.
    de Baere T, Auperin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.CrossRefGoogle Scholar
  21. 21.
    Botsa E, Poulou LS, Koutsogiannis I, et al. CT-guided radiofrequency ablation in children. Pediatr Radiol. 2014;44(11):1421–5.CrossRefGoogle Scholar
  22. 22.
    Gomez FM, Patel PA, Stuart S, Roebuck D. Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children. Pediatr Radiol. 2014;44:1281–9.CrossRefGoogle Scholar
  23. 23.
    Saumet L, Deschamps F, Marec-Berard P, et al. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience. Pediatr Hematol Oncol. 2015;32(1):41–9.CrossRefGoogle Scholar
  24. 24.
    Hoffer FA. Interventional oncology: the future. Pediatr Radiol. 2011;41:S201–6.CrossRefGoogle Scholar
  25. 25.
    Hoffer FA, Daw NC, Xiong X, et al. A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer. 2009;115(6):1328–37.CrossRefGoogle Scholar
  26. 26.
    Yevich S, Gaspar N, Tselikas L, et al. Percutaneous computed tomography-guided thermal ablation of pulmonary osteosarcoma metastases in children. Ann Surg Oncol. 2016;23(4):1380–6.CrossRefGoogle Scholar
  27. 27.
    Dunn CL, McLean TW, Lucas JT, Clark H. Successful radiofrequency ablation for recurrent pulmonary hepatoblastoma. Pediatr Blood Cancer. 2015;62(12):2242.CrossRefGoogle Scholar
  28. 28.
    Van Laarhoven S, van Baren R, Tamminga RY, et al. Radiofrequency ablation in the treatment of liver tumors in children. J Pediatr Surg. 2012;47(3):e7–12.CrossRefGoogle Scholar
  29. 29.
    Liu B, Zhou L, Huang G, et al. First experience of ultrasound-guided percutaneous ablation for recurrent hepatoblastoma after liver resection in children. Sci Rep. 2015;18(5):16805.CrossRefGoogle Scholar
  30. 30.
    Ye J, Shu Q, Li M, Jiang TA. Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence. Pediatr Radiol. 2008;38:1021–3.CrossRefGoogle Scholar
  31. 31.
    Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer. 2012;48(10):1543–9.CrossRefGoogle Scholar
  32. 32.
    Czauderna P, Haeberle B, Hiyama E, et al. The children’s hepatic tumors international collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101.CrossRefGoogle Scholar
  33. 33.
    Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28.CrossRefGoogle Scholar
  34. 34.
    Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours; a prospective, intention to treat, multicenter clinical trial (the RAPTURE) study. Lancet Oncol. 2008;9(7):621–8.CrossRefGoogle Scholar
  35. 35.
    Cerfolio RJ, McCarthy T, Bryant AS. Non-imaged pulmonary nodules discovered during thoracotomy for metastasectomy by lung palpation. Eur J Cardiothorac Surg. 2009;35(5):786–91.CrossRefGoogle Scholar
  36. 36.
    Kayton ML, Huvos AG, Casher J, et al. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Ped Surg. 2006;41(1):200–6.CrossRefGoogle Scholar
  37. 37.
    Karplus G, McCarville MB, Smeltzer MP, et al. Should contralateral exploratory thoracotomy be advocated for children with osteosarcoma and early unilateral pulmonary metastases? J Pediatr Surg. 2009;44(4):665–71.CrossRefGoogle Scholar
  38. 38.
    de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  • Steven Yevich
    • 1
  • Marco Calandri
    • 1
  • Guillaume Gravel
    • 1
  • Brice Fresneau
    • 2
  • Laurence Brugières
    • 2
  • Dominique Valteau-Couanet
    • 2
  • Sophie Branchereau
    • 3
  • Christophe Chardot
    • 4
  • Isabelle Aerts
    • 5
  • Thierry de Baere
    • 1
  • Lambros Tselikas
    • 1
  • Frederic Deschamps
    • 1
  1. 1.Interventional Radiology DepartmentGustave RoussyVillejuifFrance
  2. 2.Pediatric and Teenage Oncology DepartmentGustave RoussyVillejuifFrance
  3. 3.Pediatric Surgery DepartmentHospital du Kremlin BicêtreVillejuifFrance
  4. 4.Pediatric Surgery DepartmentHospital Necker enfants maladesParisFrance
  5. 5.Pediatric and Teenage Oncology DepartmentInstitut CurieParisFrance

Personalised recommendations